Fasting Plasma C-peptide Level Predicts the Response of Glucagon-like Peptide-1 Agonist (Exenatide) Addition to Metformin Monotherapy in Obese Type 2 Diabetics
ABSTRACT
Aim: to evaluate the predictive ability of serum C-peptide level to attain glycemic control targets by adding a glucagon-like peptide-1 receptor agonist (GLP1-RA) to metformin monotherapy in patients with type 2 diabetes and obesity.
Materials and methods: This is a retrospective study, in which we enrolled 44 consecutive obese type 2 diabetic patients who were on metformin monotherapy and have inadequate glycemic control (HbA1c >7% and <10%). Twice daily GLP1-RA (10 mcg exenatide injection) was added to the treatment. Regardless of the initial HbA1c level, treatment success was considered as an HbA1c level below 7%.
Results: When we compared the initial and the sixth month measurements of body weight, BMI, fasting glucose and c-peptide, we found a reduction for all parameters (p<0.01). 27 (61.4%) patients were achieved treatment success. Baseline C-peptide level was correlated with HbA1c at sixth month (r:0.4, p:0.01). Baseline fasting plasma c-peptide level was an independent predictor of successful glycemic control [exp.B: 6.6 (1.63-26-9) p:0.008]. Baseline plasma C-peptide level of 2.56 ng/mL was the best cut-off value for prediction of treatment success.
Conclusion: Initial fasting plasma c-peptide level can predict the treatment response of the GLP1-RA add on to metformin monotherapy in obese type 2 diabetics.
Keywords: C-peptide, type 2 diabetes, GLP-1 RA, exenatide
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Clinical Research |
Authors | |
Early Pub Date | August 30, 2022 |
Publication Date | August 30, 2022 |
Submission Date | April 17, 2022 |
Acceptance Date | July 20, 2022 |
Published in Issue | Year 2022 Volume: 39 Issue: 3 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.